Prince A M, Brotman B, Richardson L, White T, Pollock N, Riddle J
J Med Virol. 1985 Apr;15(4):421-8. doi: 10.1002/jmv.1890150411.
To provide background for future hepatitis A vaccine trials, sera were collected from 0- to 4-year-old Liberian infants and their mothers on two occasions an average of 14.75 months apart and tested for antibody to hepatitis A virus (anti-HAV). The prevalence of anti-HAV rose from 2.5% in infants 0-6 months of age to 70% in children 3-4 years of age and did not differ between male and female infants. The annual incidence of new infections was slightly lower in the first year of life (35%) than in the subsequent 3 years, when it averaged 45%. The presence of HBV infection did not affect the incidence of HAV seroconversion. No clinical hepatitis was recognized in the subjects who seroconverted. Dual hepatitis A and B virus infection were observed; these were all clinically inapparent. The extraordinary incidence of HAV infection documented in the present study offers an opportunity for vaccine efficacy trials requiring minimal numbers of subjects.
为给未来的甲型肝炎疫苗试验提供背景资料,从利比里亚0至4岁婴儿及其母亲身上采集血清,分两次进行,两次间隔平均为14.75个月,并检测甲型肝炎病毒抗体(抗-HAV)。抗-HAV的流行率从0至6个月龄婴儿的2.5%上升至3至4岁儿童的70%,且男女婴儿之间无差异。新感染的年发病率在生命的第一年(35%)略低于随后3年,随后3年的平均发病率为45%。乙肝病毒感染的存在并不影响甲型肝炎血清学转换的发生率。血清学转换的受试者中未发现临床型肝炎。观察到甲型和乙型肝炎病毒双重感染;这些感染在临床上均无明显症状。本研究记录的甲型肝炎感染的高发病率为需要最少受试者数量的疫苗效力试验提供了机会。